Press release
Severe Atopic Dermatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharma, SCM Lifescience, Sun Pharma, Brickell Biotech,, AstraZeneca, Kyowa Kirin, UCB Biopharma
To Know in detail about the Severe Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Atopic Dermatitis Market Forecast
https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Severe Atopic Dermatitis Market Report:
• The Severe Atopic Dermatitis market size was valued approximately USD 10,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2024, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced interim results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe Severe Atopic Dermatitis. The findings revealed a positive safety and efficacy profile, bolstering the continued development of soquelitinib for Severe Atopic Dermatitis and highlighting the potential of ITK inhibition as a new therapeutic approach for other immune-related diseases.
• In November 2024, Concerto Biosciences administered the first dose in a Phase I trial of its three-strain live biotherapeutic product, ENS-002, designed to treat Severe Atopic Dermatitis. ENS-002 targets Staphylococcus aureus (S. aureus), a major contributor to skin inflammation, and is being developed to address this condition.
• In October 2024, Eli Lilly's EBGLYSS showed significant improvement in skin condition and itch relief for patients with moderate-to-severe Severe Atopic Dermatitis, as highlighted by new Phase IIIb ADapt study results. These outcomes are particularly notable for individuals who did not respond adequately to the commonly prescribed dupilumab. The 24-week, open-label Phase IIIb ADapt study evaluated the safety and efficacy of EBGLYSS in patients aged 12 to under 18 years who had previously received dupilumab treatment.
• In September 2024, Galderma has announced plans to present new findings from the ARCADIA and OLYMPIA clinical trial programs, which evaluate nemolizumab for Severe Atopic Dermatitis and prurigo nodularis, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam. Scheduled for Wednesday, September 25, the presentations will include late-breaking data on long-term efficacy and safety from an interim analysis of the Phase III ARCADIA long-term extension study and novel biomarker analyses in adolescents and adults with moderate-to-severe Severe Atopic Dermatitis. Additionally, Phase IIIb OLYMPIA DURABILITY study results showcasing the durability of nemolizumab's response in adults with prurigo nodularis will also be shared.
• In August 2024, Lynk Pharmaceuticals announced promising results from its Phase Ib clinical trial of LNK01004, a novel topical therapy for Severe Atopic Dermatitis. This randomized, double-blind, placebo-controlled, multicenter study evaluated the safety, tolerability, and pharmacokinetics of LNK01004 in adults with mild to moderate Severe Atopic Dermatitis.
• In the 7MM, the United States had the largest market size for Severe Atopic Dermatitis in 2023, with Japan following closely behind.
• DUPIXENT, the first approved therapy for Severe Atopic Dermatitis (AD), generates around USD 2 billion in revenue by focusing on the moderate-to-severe patient group through targeted therapies and biologics.
• In 2023, there were approximately 53,348,000 diagnosed cases of Severe Atopic Dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.
• In 2023, there were approximately 72,435,000 prevalent cases of Severe Atopic Dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.
• In 2023, the total diagnosed cases of Severe Atopic Dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.
• Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
• Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
• The Severe Atopic Dermatitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Atopic Dermatitis pipeline products will significantly revolutionize the Severe Atopic Dermatitis market dynamics.
Severe Atopic Dermatitis Overview
Severe Atopic Dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itchy, red, and dry skin. It is most frequently seen in children but can occur at any age. Severe Atopic Dermatitis is part of a group of allergic conditions, often referred to as the atopic triad, which also includes asthma and allergic rhinitis (hay fever).
Get a Free sample for the Severe Atopic Dermatitis Market Report:
https://www.delveinsight.com/report-store/severe-atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Severe Atopic Dermatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Severe Atopic Dermatitis Epidemiology Segmentation:
The Severe Atopic Dermatitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Severe Atopic Dermatitis
• Prevalent Cases of Severe Atopic Dermatitis by severity
• Gender-specific Prevalence of Severe Atopic Dermatitis
• Diagnosed Cases of Episodic and Chronic Severe Atopic Dermatitis
Download the report to understand which factors are driving Severe Atopic Dermatitis epidemiology trends @ Severe Atopic Dermatitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Severe Atopic Dermatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Severe Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Severe Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Severe Atopic Dermatitis Therapies and Key Companies
• Bermekimab: Janssen Pharmaceutical
• FB825: Oneness Biotech
• Lebrikizumab: Eli Lily
• Nemolizumab: Galderma
• B244: AOBiome
• Ruxolitinib: Incyte
• Difelikefalin: Cara Therapeutics
• Roflumilast: Arcutis Biotherapeutics
• Rocatinlimab: Amgen/Kyowa Kirin
• Tapinarof: Dermavant Sciences
• KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics
• Etrasimod: Pfizer/Arena pharmaceuticals
• BMX-010: BioMimetix
Discover more about therapies set to grab major Severe Atopic Dermatitis market share @ Severe Atopic Dermatitis Treatment Market
https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Severe Atopic Dermatitis Market Drivers
• Rising prevalence of Severe Atopic Dermatitis
• Escalating expenditure on healthcare
• Approvals of JAK inhibitors
• Potential Emerging Therapies for Severe Atopic Dermatitis and pruritus
• Increasing awareness about the condition
Severe Atopic Dermatitis Market Barriers
• Over-the-counter medications
• Outdated treatment recommendations
• Poor prognosis and treatment adherence
• Lack of timely diagnosis
• Management of Severe Atopic Dermatitis in the primary care setting
Scope of the Severe Atopic Dermatitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
• Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
• Severe Atopic Dermatitis Therapeutic Assessment: Severe Atopic Dermatitis current marketed and Severe Atopic Dermatitis emerging therapies
• Severe Atopic Dermatitis Market Dynamics: Severe Atopic Dermatitis market drivers and Severe Atopic Dermatitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Severe Atopic Dermatitis Unmet Needs, KOL's views, Analyst's views, Severe Atopic Dermatitis Market Access and Reimbursement
To know more about Severe Atopic Dermatitis companies working in the treatment market, visit @ Severe Atopic Dermatitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Severe Atopic Dermatitis Market Report Introduction
2. Executive Summary for Severe Atopic Dermatitis
3. SWOT analysis of Severe Atopic Dermatitis
4. Severe Atopic Dermatitis Patient Share (%) Overview at a Glance
5. Severe Atopic Dermatitis Market Overview at a Glance
6. Severe Atopic Dermatitis Disease Background and Overview
7. Severe Atopic Dermatitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Severe Atopic Dermatitis
9. Severe Atopic Dermatitis Current Treatment and Medical Practices
10. Severe Atopic Dermatitis Unmet Needs
11. Severe Atopic Dermatitis Emerging Therapies
12. Severe Atopic Dermatitis Market Outlook
13. Country-Wise Severe Atopic Dermatitis Market Analysis (2020-2034)
14. Severe Atopic Dermatitis Market Access and Reimbursement of Therapies
15. Severe Atopic Dermatitis Market Drivers
16. Severe Atopic Dermatitis Market Barriers
17. Severe Atopic Dermatitis Appendix
18. Severe Atopic Dermatitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports by DelveInsight
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Atopic Dermatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharma, SCM Lifescience, Sun Pharma, Brickell Biotech,, AstraZeneca, Kyowa Kirin, UCB Biopharma here
News-ID: 3895272 • Views: …
More Releases from DelveInsight Business Research
Spinal Cord Injury Market Poised for Sustained Growth Amid Advancements in Treat …
DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Spinal Cord Injury Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the key facts of the…
Pulmonary Arterial Hypertension Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 50+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Pulmonary Arterial Hypertension Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial…
Irritable Bowel Syndrome Pipeline 2026: In-depth Clinical Trials Analysis and Em …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Irritable Bowel Syndrome pipeline constitutes 15+ key companies continuously working towards developing 20+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
Pancreatic Cancer Market Growth Outlook 2036: Epidemiology, Pipeline Therapies, …
The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.
DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany,…
More Releases for Severe
Severe Asthma Clinical Trial Pipeline Analysis: 30+ Key Companies Shaping the Fu …
DelveInsight's Severe Asthma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Severe Asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Severe Asthma pipeline domain.
Key takeaways from the Severe Asthma Clinical Trial Landscape Report
• DelveInsight's Severe Asthma pipeline report depicts a robust space with 30+ active players working to develop 30+…
Painkillers for particularly severe back pain
Not all back pain is mild. While many complaints subside after a few days with rest and mild painkillers, there are situations in which the intensity is significantly higher. Those affected describe stabbing, deep-seated or radiating pain that significantly restricts even simple movements.
Particularly in cases of disc problems, severe muscle spasms or nerve root irritation, the strain can be so severe that targeted pain therapy is necessary.
The aim is…
PMS or PMDD? Understanding Severe Premenstrual Mood Changes
Many women notice mood shifts before their period. They may feel more emotional, tired, or irritable. This is often labeled PMS. For some, symptoms are mild and manageable. For others, they are intense and disruptive.
When mood changes become severe, especially when they affect work, school, or relationships, it may be something more serious. That condition is called PMDD.
Understanding the difference between typical premenstrual symptoms and a psychiatric condition can help…
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
